Last updated on June 2017

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotrophic Hypogonadism


Brief description of study

Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotrophic Hypogonadism

Detailed Study Description

The purpose of this study is to evaluate the safety and efficacy of BGS649 in male obese subjects with hypogonadotrophic hypogonadism. All subjects will be treated for a maximum of 24 weeks. Some subjects who complete 24 weeks of treatment will be invited to participate in a 6-month blinded safety extension study (Protocol MBGS206). The study is planned to enroll 268 subjects.

Clinical Study Identifier: TX150137

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.